MedTechDive, January 27, 2025: FDA webpages on how to improve diversity in clinical trials and other topics were immediately removed after Trump was inaugurated and ordered numerous federal agencies to pause in communicating with the public. We explain that diversity in clinical trials is not affirmative action, it is needed to ensure that medical products are safe and effective for males and females and for people of all ages and races. The new FDA Commissioner hasn’t been confirmed, so who made these decisions?
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
In debate over obesity medications, FDA shifts toward importance of drugs in subtle ways
STAT News, January 10, 2025: The FDA’s new guidance to Pharma on how to develop weight loss drugs reflects a cultural shift that treats drugs as the first resort instead of the last resort if changing eating habits and exercising doesn’t work.
Read More »Beyond Step Counting: Wearable Tech Promises Medical-grade Data
Barron’s, January 8, 2025: Barron’s article from AFP News describes the promise of new wearable medical devices for improving health and the criticisms by NCHR’s Diana Zuckerman and other experts regarding the lack of certainty about their accuracy due to low regulatory standards by the FDA. This makes it difficult to know which products are accurate and which ones aren’t.
Read More »FDA Off-Label Drug Guidance: 3 Things to Know
Law360, January 7, 2025: FDA Final Guidance on promoting off-label uses of approved drugs will increase sales but we explain it misleads doctors and patients about safety and efficacy because unapproved uses of drugs are not proven to be safe or effective.
Read More »Inside The U.S. Effort To Boost The Natural Grass Industry
Forbes, December 22, 2024: This excellent article in Forbes explains how USDA is trying to boost the natural grass industry for its advantages compared to artificial grass and its importance to the economy. NCHR agrees that natural grass is safer than plastic grass and explains why.
Read More »